Developments Rein doses first patient in Phase 2 trial of LTI-03 in IPF Rein Therapeutics (NASDAQ: RNTX) has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with... March 3, 2026